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Background: Identifying metabolomic profiles of children with asthma has the
potential to increase understanding of asthma pathophysiology.
Objective: To identify differences in plasma metabolites between children with and
without current asthma at mid-childhood.
Methods: We used untargeted mass spectrometry to measure plasma metabolites
in 237 children (46 current asthma cases and 191 controls) in Project Viva, a
birth cohort from eastern Massachusetts, USA. Current asthma was assessed at
mid-childhood (mean age 8.0 years). The ability of a broad spectrum metabolic
profile to distinguish between cases and controls was assessed using partial least
squares discriminant analysis. We used logistic regression models to identify indi-
vidual metabolites that were differentially abundant by case–control status. We
tested significant metabolites for replication in 411 children from the VDAART
clinical trial.
Results: There was no evidence of a systematic difference in the metabolome of
children reporting current asthma vs. healthy controls according to partial least
squares discriminant analysis. However, several metabolites were associated with
odds of current asthma at a nominally significant threshold (P < .05), including a
metabolite of nicotinamide (N1-Methyl-2-pyridone-5-carboxamide (Odds Ratio
(OR) = 2.8 (95% CI 1.1-8.0)), a pyrimidine metabolite (5,6-dihydrothymine (OR = 0.4
(95% CI 0.2-0.9)), bile constituents (biliverdin (OR = 0.4 (95%CI 0.1-0.9), tauro-
cholate (OR = 2.0 (95% CI 1.2-3.4)), two peptides likely derived from fibrinopeptide
A (ORs from 1.6 to 1.7), and a gut microbiome metabolite (p-cresol sulphate
OR = 0.5 (95% CI 0.2-0.9)). The associations for N1-Methyl-2-pyridone-5-carboxa-
mide and p-cresol sulphate replicated in the independent VDAART population
(one-sided P values = .03-.04).
Conclusions and Clinical Relevance: Current asthma is nominally associated with
altered levels of several metabolites, including metabolites in the nicotinamide path-
way, and a bacterial metabolite derived from the gut microbiome.
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1 | INTRODUCTION
Asthma is the most common chronic illness in U.S. children, and
results in substantial morbidity as well as health care costs, with over
$50 billion dollars spent annually.1 Asthma exacerbations are the
most common health-related cause of lost school days,1 rendering
asthma a considerable public health burden. Asthma is a heritable
disease with both environmental and genetic components.2,3 A num-
ber of molecular determinants have been identified for asthma,4 yet
much remains unknown about how these molecular variants impact
the disease. Metabolomics, the systematic analysis of all metabolites
in a biological system, including carbohydrates, peptides, amino acids,
organic acids, nucleotides and lipids, has emerged as a powerful tool
to identify new biomarkers for several diseases, and may help iden-
tify novel pathways associated with complex disease. Metabolite
fluctuations may be more accurate disease markers than transcrip-
tional, translational or post-translational changes, as they represent
an integrated pathophysiologic profile that captures genetic and
environmental interactions. Changes in metabolite profiles associated
with chronic disease status in epidemiological studies may highlight
important metabolites or metabolic pathways to interrogate in both
in vitro and in vivo studies of underlying pathophysiological mecha-
nisms.
Investigators have successfully identified metabolite biomarkers
for Type 2 Diabetes, Alzheimer’s disease and cardiovascular dis-
ease,5-8 leading to the discovery of novel disease pathways for these
conditions. Existing asthma metabolomic studies9-22 have reported
promising findings, identifying biologically plausible metabolites
related to tricarboxylic acid (TCA) metabolism, hypermethylation,
phospholipid regulation, hypoxic and oxidative stress, immune reac-
tion and inflammation that have been associated with asthma and
asthma severity. Nevertheless, the studies to date are limited by
diagnostic heterogeneity, sample size, and number of metabolites,
and most findings are yet to be replicated in independent popula-
tions. As such, the use of metabolomics in asthma studies remains in
the early stages with much knowledge to be gained.
The goal of this study is to identify differences in metabolomic
profiles for children with and without a current diagnosis of asthma,
using an untargeted metabolomic profiling approach. We sought to
determine whether children with current asthma have altered meta-
bolic profiles as compared to controls without current asthma. Our
goals were to (i) determine the ability of a broad spectrum metabolic
profile to discriminate between current asthma cases vs. controls (ii)
identify specific individual metabolites associated with current
asthma and (iii) validate these findings using an independent popula-
tion.
2 | METHODS AND MATERIALS
2.1 | Study population
2.1.1 | Discovery population
Project Viva is an ongoing longitudinal pre-birth cohort study of chil-
dren recruited from Atrius Harvard Vanguard Medical Associates, a
multispecialty group practice in eastern Massachusetts. The purpose
of Project Viva is to study the effect of environmental exposures on
maternal and child health. Details of the study design and recruit-
ment have been previously reported.23 The Institutional Review
Board of Harvard Pilgrim Health Care approved the study protocols.
All mothers participating in the study provided written informed con-
sent and the children provided verbal assent. A total of 1,116
mother–child pairs (with children aged 6-10 years) attended an in-
person mid-childhood study visit and 648 assenting children
provided fasting blood samples. Metabolomic assays were originally
performed for a study of childhood obesity and metabolomics in
Project Viva.24 Given funding limitations, we selected 300 children
for analysis, deliberately oversampling for maternal and child for
obesity. Subjects were oversampled for obesity as the original
analysis was focused on studying obesity.24
After further exclusion of 38 children with inadequate plasma
volume for the metabolomic assays, 262 children (84 obese, 28
overweight and 150 normal weight participants) had metabolomic
data. Of 262, we excluded from this analysis 21 children with past
asthma diagnosis, and four with inadequate information on current
asthma. Thus, the final analytic sample included 237.
We assessed current asthma during the mid-childhood visit
(mean age 8.0 years). We defined current asthma in mid-childhood
as maternal report of ever diagnosed with asthma by a healthcare
professional (assessed on the mid-childhood questionnaire) plus
either taking asthma medications in the past 12 months or wheezing
symptoms the past 12 months. This analysis included 46 cases with
current asthma, and 191 controls who had never reported a past
asthma diagnosis, and who did not report wheezing or use of asthma
medications in the past 12 months. We also collected information
from in-person interviews and questionnaires on maternal age at
enrollment, maternal education (a marker of socio-economic status),
smoking during pregnancy and child age, gender and race/ethnicity.
Information on asthma medication use and asthma severity was also
collected from in-person interviews and questionnaires. Height and
weight data collected at the mid-childhood visit were used to com-
pute BMI z-scores based on CDC 2000 age and gender-specific ref-
erence data.25 Allergen sensitization was defined as any specific IgE
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level of 0.35 IU/ml or greater to common indoor allergens
(Dermatophagoides farinae, cat, dog and cockroach), mold allergens
(Alternaria or Aspergillus species), food allergens (egg white, milk and
soy bean), or outdoor allergens (rye grass and ragweed).
Plasma metabolomic profiling for Project Viva was performed at
MetabolonTM for 262 children based on availability of archived
biospecimens for a separate study of metabolomics and obesity sta-
tus.24 Untargeted metabolomic profiling was performed using multi-
platform mass spectrometry (MS); detailed descriptions of sample
preparation and metabolite identification procedures have been pre-
viously published (see Appendix S1 for additional details).26 Samples
were prepared using the automated MicroLab STAR system from
Hamilton Company for both Project Viva and VDAART. Several
recovery standards were added prior to the first step in the extrac-
tion process for QC purposes. The resulting extract was divided into
four fractions: one for analysis by UPLC/MS/MS (positive mode),
one for UPLC/MS/MS (negative mode), one for GC/MS and one for
backup. Samples were placed briefly on a TurboVap (Zymark) to
remove the organic solvent. Each sample was then frozen and dried
under vacuum. Samples were then prepared for the appropriate
instrument, as described below.
Briefly, the analysis was performed using three platforms: UPLC/
MS/MS (positive mode), UPLC/MS/MS (negative mode) and GC/MS,
with pooled samples included throughout the analytical run for quality
control purposes. Raw data were extracted, peak-identified and qual-
ity-control processed using Metabolon Inc. hardware and software.
Semi-quantitative concentrations (expressed in arbitrary units) of 345
known biochemicals were obtained. Metabolites were identified by
comparison to library entries of purified standards or recurrent
unknown entities. We included both endogenous and exogenous
metabolites in our analyses. Missing values were imputed with half of
the minimum value for that compound. Metabolite intensities were log
transformed to normalize them and pareto-scaled to reduce the varia-
tion in fold-change differences between the features. See Appendix S1
for full details of the Metabolomic Profiling Procedures.
2.1.2 | Replication population
For replication of our findings in Project Viva, we used plasma sam-
ples of children born to mothers enrolled in the Vitamin D Antenatal
Asthma Reduction Trial (VDAART) clinical trial; a two arm, double-
blind, placebo controlled, randomized, clinical trial of Vitamin D, to
determine whether higher vitamin D intake and levels in the preg-
nant mother will prevent asthma and allergy in childhood.27 Pregnant
women (who had or whose partner had allergies/asthma) were ran-
domized (n = 881) during the first trimester of pregnancy (10-
18 weeks) to one of two treatment arms of a clinical trial: 4000 IU
Vitamin D+ prenatal vitamins or 400 IU Vitamin D+ prenatal vita-
mins. Of the 810 live births, 411 of had non-fasting plasma samples
available at age three years for metabolomics analysis (108 asthma
cases, 303 controls). Metabolomic profiling for VDAART was per-
formed at MetabolonTM, using a platform similar to the one utilized
for Project Viva (see Appendix S1 for details). We used physician’s
diagnosis of asthma to define cases in VDAART at age three follow-
up.28 Parental report of physician’s diagnosis of asthma was taken
directly from the offspring questionnaires.
2.2 | Statistical analysis
Analyses were conducted in R.29 Differences in maternal and child
demographic characteristics between cases and controls were
assessed using t-tests for continuous variables and chi-square tests
for categorical variables.
2.2.1 | Partial least squares discriminant analysis
Metabolite features were analysed as measured LC-MS peak areas,
which are proportional to feature concentration and can be com-
pared for any given metabolite (relative quantitation). Partial least
squares discriminant analysis (PLS-DA) was conducted using
MetaboAnalyst v.2.5 (http://www.metaboanalyst.ca/)30 to determine
the combined ability of the 345 identified metabolites to discrimi-
nate asthma cases from controls. PLS-DA identifies latent factors, or
components, that best describe the relationships between the
metabolites, while best predicting asthma status. A sevenfold internal
cross-validation procedure was implemented to guard against model
over-fitting, and the overall significance of the model’s discriminatory
ability was evaluated using permutation testing; specifying ‘predic-
tion accuracy during training’ and 2000 permutations.
2.2.2 | Individual metabolite analysis
We also conducted logistic regression on individual metabolites, to
determine their relationship to asthma case status. Models were
adjusted for maternal age, maternal education, smoking during preg-
nancy, child’s gender, age, BMI z-score and race/ethnicity. Associa-
tions were expressed as odds ratios (95%CI) for current asthma per
unit increase in metabolite.
2.2.3 | Replication of significant findings
For replication, metabolites significantly associated with asthma in
Project Viva were tested in an independent cohort of children from
the VDAART clinical trial. We performed logistic regression analysis
to determine if these metabolites were associated with asthma diag-
nosis at age 3 years. Analyses were adjusted for child’s age, gender,
BMI, race/ethnicity, maternal education level and maternal age. We
report one-sided P values for the replication analysis.
3 | RESULTS
3.1 | Discovery population
Characteristics of the discovery population are presented in Table 1.
Of the 237 children in Project Viva, 52.3% were female and 19.4%
had a mother-reported a diagnosis of current asthma. The mean
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(SD) age was 8.0 (0.9) years. The majority of children with cur-
rent asthma were also sensitized to allergens. Seventy-two percent
had a positive specific IgE test (≥0.35 IU/mL) to at least one of the
specific indoor, outdoor or food allergens tested. In contrast, 49% of
control subjects were sensitized to allergens. There were also nota-
ble differences between children with vs. without current asthma
with respect to maternal age (30.3 vs 32.5 years, P = .02) and edu-
cation (37.8% vs 63.9% college graduates, P = .002) and child age
(8.4 vs 7.9 years, P = .02), race/ethnicity (26.1% vs 64.4% white,
P ≤ .0001) and BMI z-scores (1.45 vs 0.66, P < .0001). There were
no differences between children with vs without current asthma
with respect to child’s gender or maternal pregnancy smoking status.
We also collected information on asthma medication use and
asthma severity in children with current asthma. The vast majority
(80%) of current asthmatics were taking inhaled corticosteroids. In
general, most current asthmatics in Project Viva showed mild to
moderate disease severity. None of the current asthmatics were hos-
pitalized in the past year for asthma. Most children with current
asthma did not require emergency treatment for asthma symptoms
in the past year (72%), although 17% reported one emergency room
visit for asthma, 9% reported visiting the emergency room 2-3 times
in the past year, with 2% reporting 3 or more visits. A little over half
of the children (58%) with current asthma occasionally missed school
because of asthma symptoms; 20% report one missed school day,
26% report 2-3 missed school days, and 11% report more than three
missed school days over a 1 year time period.
In VDAART, cases of current asthma were generally mild. Only
38% of children received any medication for wheezing, wheezy
bronchitis or asthma since their last follow-up. Seventeen percent of
current asthmatics report seeing a doctor because of wheezing,
asthma, wheezing or asthmatic bronchitis since their last follow-up.
3.2 | Replication population
Of the 411 children with available metabolomics data in the
VDAART population, 219 (53%) were male and 108 (26%) developed
asthma by age three. VDAART participants were of diverse race/eth-
nic backgrounds, and were 48% African American, 33% white and
19% other race. Of the children with current asthma in VDAART,
58% were sensitized to at least one of the indoor, outdoor or food
allergens tested, while approximately half (48%) of the control sub-
jects were sensitized to allergens.
3.3 | Partial least squares discriminant analysis
There was no evidence in these analyses that a specific profile signa-
ture derived from the 345 identified metabolites differed between
asthma cases and controls in Project Viva (Figure S1). After seven-
fold internal cross-validation accuracy was 0.8, but the R2 and Q2
were only 0.25 and 0.05, respectively, for the first component, indi-
cating that the model was not robust. This was confirmed by the
permutation testing (permuted P = .134).
TABLE 1 Demographics of discovery population, project viva (N = 237)
Total
Current asthma at mid-childhood
P-value
Yes No
N = 237 N = 46 (19.4%) N = 191 (80.6%)
N (%) or mean (SD)
Mother
Age at enrollment, years 32.1 (5.8) 30.3 (5.8) 32.5 (5.8) .02
Smoking status, %
Never 151 (63.7) 30 (65.2) 121 (63.4) .15
Former smoker (before pregnancy) 51 (21.5) 6 (13.0) 45 (23.6)
Current smoker (during pregnancy) 35 (14.8) 10 (21.7) 25 (13.1)
Education status, %
Not college graduate 97 (41.1) 28 (62.2) 69 (36.1) .002
College graduate 139 (58.9) 17 (37.8) 122 (63.9)
Child
Gender: Female, % 124 (52.3) 28 (60.9) 96 (50.3) .25
Age at mid-childhood visit, years 8.0 (0.9) 8.4 (1.2) 7.9 (0.7) .02
Child race/ethnicity, %
Black 56 (23.6) 23 (50.0) 33 (17.3) <.0001
White 135 (57.0) 12 (26.1) 123 (64.4)
Other 46 (19.4) 11 (23.9) 35 (18.3)
BMI z-score at mid-childhood 0.81 (1.15) 1.45 (1.14) 0.66 (1.10) <.0001
Allergen Sensitizationa 114 (53.0) 28 (71.8) 86 (48.9) .009
aAllergen sensitization numbers reflect some missing data; 215 subjects out of 237 had allergen sensitization testing.
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3.4 | Individual metabolite analysis
Of all of the metabolites tested in Project Viva for associations with
current asthma case status, none were statistically significant after
adjustment for multiple comparisons. However, 10 metabolites were
nominally significant at the P < .05 level (Table 2). A one unit
increase in N1-Methyl-2-pyridone-5-carboxamide, a metabolite in
the nicotinamide pathway, was associated with an increased odd of
asthma (OR = 2.79, 95% CI 1.10-7.97). The relationship between
N1-Methyl-2-pyridone-5-carboxamide and asthma case status was
replicated (Table 3) in the VDAART cohort (OR = 1.27, P = .04 (one-
sided P value)). The pyrimidine metabolite 5,6-dihydrothymine was
associated with reduced odds of asthma (OR = 0.44, 95% CI 0.21-
0.86) in Project Viva (Table 2), but showed the opposite direction of
effect in VDAART (Table 3). Metabolomics profiling also uncovered
two peptides (DSGEGDFXAEGGGVR and ADSGEGDFXAEGGGVR)
associated with current asthma in Project Viva. An NCBI protein
blast search revealed fibrinopeptide A as the top hit (highest maxi-
mum alignment score and lowest E value) for these peptides. Bile
constituents taurocholate and biliverdin were also related to asthma
case status. Taurocholate, a bile salt involved in fat emulsification,
was associated with current asthma (OR = 2.03, 95% CI 1.22-3.42),
while biliverdin, a bile pigment and product of heme catabolism was
associated with decreased odds of current asthma (OR = 0.35 95%
CI 0.14-0.87). p-cresol sulphate, a bacterial metabolite originating
from the gut microbiome, was linked to decreased odds of current
asthma (OR = 0.47, 95% CI 0.23-0.94). This association was repli-
cated in the VDAART study (Table 3). Other metabolites demon-
strating lower levels amongst asthmatic cases in Project Viva were
cortisone (a naturally occurring glucocorticoid), tryptophan betaine
(from dietary intake of legumes), and 1-docosapentaenoylglycero-
phosphocholine (22:5), a lysophosphospholipid formed by hydrolysis
of phosphatidylcholine by phospholipase A2. Spectra for the two
metabolites associated with current asthma in both the discovery
and replication cohort (N1-Methyl-2-pyridone-5-carboxamide and
p-cresol sulphate) are shown in Figures S2 and S3.
Based on prior reports, we looked to see if plasma cortisone was
lower in current asthmatics on ICS as compared to untreated current
asthmatics in Project Viva. We did not see an association between
ICS use and lower cortisone levels in current asthma cases (P > .9
for t-test comparisons). However, the very high ICS treatment rates
in current asthmatics (80%) meant that a comparison with untreated
current asthmatics was likely underpowered.
4 | DISCUSSION
We identified metabolites associated with asthma by profiling the
plasma metabolome in children from two longitudinal birth cohort
studies. In Project Viva, current asthma was associated with alter-
ations in metabolites from the nicotinamide pathway, pyrimidine
metabolism, fibrinogen-associated peptides, bile metabolites and
p-cresol sulphate, a microbial metabolite derived from the gut micro-
biome. Cortisone, a metabolite inversely associated with ICS use,31
was decreased in current asthmatics. The association between
asthma case status and two of the top metabolites (the bacterial
metabolite p-cresol sulphate from the gut microbiome, and a nicoti-
noamide pathway metabolite) were replicated in a second cohort,
the VDAART clinical trial.
Our study shows a new potential link between higher levels of
plasma p-cresol sulphate and decreased odds of asthma. This associa-
tion was replicated in an independent cohort. p-cresol sulphate is a
microbial metabolite that may reflect gut microbiome composition.32
Gut microbes have long been hypothesized to interact with the
immune system in ways that may alter risk of allergies and asthma, and
a number of publications now show compositional differences in the
gut microbiome when allergic disease risk factors or allergic disease
phenotypes are present.33–38 It has been hypothesized that p-cresol
sulphate may indicate a gut microbiome enterotype dominated by Bac-
teroides,32 a genera containing multiple taxa including B. Fragilis, a spe-
cies with strong experimental evidence for restoring Th1/Th2
balance.39 While our observed association between p-cresol sulphate
TABLE 2 Metabolites associated with Current Asthma in Project Viva
Pathway/Grouping Metabolite
Odds Ratio (95% CI) for
Current Asthmaa
Nicotinate and Nicotinamide Metabolism N1-Methyl-2-pyridone-5-carboxamide 2.79 (1.10-7.97)
Bile Constituents Taurocholate 2.03 (1.22-3.42)
Biliverdin 0.35 (0.14-0.87)
Pyrimidine Metabolism 5,6-dihydrothymine 0.44 (0.21-0.86)
Microbial Metabolite p-cresol sulphate 0.47 (0.23-0.94)
(Putative) Fibrinopeptide A DSGEGDFXAEGGGVRa 1.57 (1.02-2.42)
ADSGEGDFXAEGGGVRa 1.68 (1.04-2.73)
Dietary Metabolites Tryptophan Betaine 0.47 (0.28-0.77)
Endogenous steroids Cortisone 0.20 (0.06-0.59)
Glycerophospholipid metabolism 1-docosapentaenoylglycerophosphocholine (22:5) 0.44 (0.22-0.88)
aOdds ratios are for a 1 unit increase in metabolite level; all odds ratios are adjusted for maternal age, maternal education, smoking in pregnancy, child’s
BMI z-score, race/ethnicity, age and gender; Odds ratios with P < .05 in bold.
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and asthma status is intriguing, further research is required to uncover
the connection between the gut microbiome, the circulating metabo-
lome, and their combined relationship to asthma.
We observed higher levels of the nicotinamide pathway metabolite
N1-Methyl-2-pyridone-5-carboxamide in asthmatic subjects vs. controls
in Project Viva, and our findings in VDAART were showed a similar rela-
tionship. The nicotinate and nicotinamide metabolic pathway has been
linked to asthma phenotypes in both in vitro and population-based
studies. One in vitro study of human airway smooth muscle demon-
strated that cells from asthmatic donors had increased expression of
NADPH (Nicotinamide Adenine Diphosphate) Oxidase, which promoted
oxidative stress and smooth muscle cell contractility.40 Other in vitro
findings show increased NADPH oxidase expression in neutrophilic
asthma, with a concomitant decrease in ciliary function of the bronchial
epithelium.41 These in vitro models provide a biological basis for our
observed association between plasma nicotinamide metabolites and
current asthma. While one other previous epidemiological study
reported alterations in nicotinamide pathway metabolites (nicotinamide
was increased in asthmatic subjects vs. controls), the sample size was
small (30 subjects in total) and there were no attempts at replication.42
Metabolomic profiles of asthmatics in our study also showed
increased levels of two similar peptides likely derived from fib-
rinopeptide A (DSGEGDFXAEGGGVR and ADSGEGDFXAEGGGVR).
Fibrinopeptide A is a short amino acid sequence located within the
alpha chain of soluble fibrinogen. Fibrinogen may play a role in
asthma pathogenesis by enhancing inflammatory response. Huang
and colleagues reported a correlation between increased plasma fib-
rinogen and reduced lung function. These investigators also found
that obese subjects, including those with asthma, tend to have
higher circulating fibrinogen levels.43 Fibrinogen cleavage products
act as TLR4 ligands, enhancing innate immune response.44 For
instance, fibrinogen cleavage products can bind Toll like receptor 4
(TLR4), priming innate immune and airway epithelial cell response to
IL-13, with downstream triggering of airway inflammation.45
Two of the metabolites with altered levels in current asthmatics,
taurocholate and biliverdin, are bile constituents. Taurocholate, a
conjugate of taurine and cholic acid, is an emulsifier of fats. Comhair
and investigators previously reported increased plasma taurocholate
in asthmatics, and we replicate that finding here in a much larger
cohort.42 Yu and colleagues also report altered levels of taurocholate
in a mouse model of OVA-induced asthma46; however, in this exper-
imental study mice with the asthma phenotype had lower, as
opposed to higher, levels of circulating taurocholate. Other experi-
mental data suggest that activity of hemoxygenase-1, the enzyme
that produces biliverdin from heme, may reduce mucous secretion in
the airways. In an in vitro study of normal human bronchial epithelial
cells, over-expression of heme oxygenase-I was associated with
reduced IL-13 induced goblet cell hyperplasia and decreased MUCA5
secretion.47 The lower levels of circulating biliverdin in asthma cases
may reflect reduced activity of heme oxygenase I, which could
potentially contribute to increased mucous production in the airways
(a common feature of asthma).
Consistent with the findings of Reinke et al,31 we also observed
decreased plasma cortisone levels in subjects with current asthma. This
finding is consistent with well-known effects of ICS (inhaled corticos-
teroid) use, which cause suppression of the hypothalamic-pituitary axis,
leading to lower production of endogenous steroids like cortisone.48
The decreased plasma cortisone levels in asthmatics vs. controls is most
likely a simple reflection of ICS use, and not an indicator of asthma
pathophysiology. Since the majority of asthmatics were treated with
ICS, we could not disentangle the effects of ICS use from those associ-
ated with current asthma status in our analysis.
Lastly, our observation that pyrimidine metabolism may be
altered in asthmatics vs. controls may have relevance for asthma
pathophysiology. A large metabolomics study in a cohort of child-
hood asthmatics demonstrated associations between pyrimidine
metabolites and three phenotypic aspects of asthma (methacholine
responsiveness, pre bronchodilator FEV1/FVC ratio and post bron-
chodilator FEV1/FVC ratio).49 However the mechanistic connection
between pyrimidine metabolism and physiological processes influ-
encing asthma remains unclear. Findings for our discovery population
and replication cohort demonstrated opposite directions of effect for
the 5,6-dihydorthymine metabolite, an inconsistency that makes the
associations difficult to interpret.
It is interesting to note that our PLS-DA analysis did not identify
any global metabolite profile differences by asthma status, whereas
analysis of individual metabolites did yield a number of biologically plau-
sible associations. One interpretation of this finding is that asthma case
TABLE 3 Replication of Significant Metabolites Associated with Current Asthma in VDAART Population
Pathway/Grouping Metabolite Odds Ratio (95% CI) for Asthmaa
P value (one sided)
for Replication
Nicotinate and Nicotinamide Metabolism N1-Methyl-2-pyridone-5-carboxamide 1.27 (0.97-1.66) .04
Bile Constituents Taurocholate 1.03 (0.89-1.20) .35
Biliverdin 1.08 (0.90-1.31) .20
Microbial Metabolite p-cresol sulphate 0.83 (0.69-1.00) .03
Pyrimidine Metabolism 5,6-dihydrothymine 1.56 (1.00-2.40) .02
Dietary Metabolite Tryptophan Betaine 1.01 (0.92-1.12) .38
Endogenous steroids Cortisone 1.30 (0.97-1.75) .04
aModels adjusted for maternal age, maternal education, child’s BMI, race/ethnicity, age and gender.
Odds ratio that replicates in the same direction of effect with P < .05 is in bold.
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status is associated with perturbations of few individual metabolites,
rather than latent variables describing global pathway alterations (shifts
in multiple correlated metabolites). An alternate explanation is that,
even with hundreds of named metabolites in our analysis, we still did
not have a broad enough coverage of underlying correlated metabolites
and their associated pathways to detect global metabolome shifts asso-
ciated with asthma case status. Instead, we may have identified individ-
ual, surrogate metabolite markers of more global pathway
perturbations, through our logistic regression analyses. As metabolite
identifications continue to expand, PLS-DA may be a more effective
tool in identifying global shifts in the metabolome of complex diseases.
Our study has several strengths. First, it is one of the largest plasma
metabolomic studies comparing asthma cases to control subjects to
date. Second, we limited potential sources of bias by controlling for con-
founders, including race, BMI and maternal educational level. Third, we
were able to replicate two of our top metabolites in an independent
cohort. Despite the strengths of our study, a few caveats deserve men-
tion. First, utilizing maternal report of doctor diagnosis of asthma, rather
than direct physician report of asthma diagnosis may have been poten-
tial source of bias in health outcome assessment. Second, while our
study is large compared to other metabolomics studies, our sample size
may have been too small to identify associations that were statistically
significant after accounting for multiple comparisons. An additional limi-
tation was that the phenotypes available for our discovery and replica-
tion cohorts were different. For Project Viva, current asthma status was
assessed in mid-childhood, whereas VDAART subjects were assessed at
age 3, when a definitive asthma diagnosis is often difficult. Also, the
racial/ethnic and socioeconomic status distributions (while accounted
for in our analyses) and different geographic locations for the primary
and replication populations, may have given rise to very different expo-
sure profiles (including diet) that could not be adjusted for in our analy-
ses. Plasma samples in Project Viva were fasting, whereas in the
replication population plasma samples were non-fasting. (The use of
non-fasting samples in VDAART may have had a particular influence on
our ability to detect an association between current asthma status and
the dietary metabolite tryptophan betaine, if recent food intake
increased the variability of this metabolite.) The study designs for Pro-
ject Viva and VDAART were also different; Project Viva is an observa-
tional epidemiology study based on an unselected population, while
VDAART is a clinical trial of prenatal vitamin D supplementation and
asthma outcomes in children with a parental history of allergies or
asthma. These discrepancies in the two cohorts may have decreased
our potential for replication; however, our ability to replicate two
metabolites in spite of these differences suggests that our replicated
associations are robust. Metabolite identification in the two populations
was not identical, which meant that we did not have the opportunity to
test for replication of the phospholipid 1-docosapentaenoylglycero-
phosphocholine (22:5) and fibrinogen peptide findings, as these were
not among the named metabolites in our replication study. It should also
be noted that while many of the metabolites associated with asthma in
our primary cohort are biologically plausible and supported by experi-
mental data in the literature, none were statistically significant after
adjustment for multiple comparisons.
In summary, our findings suggest that current asthma is associ-
ated with perturbations in pathways including metabolism of nicoti-
namide and pyrimidines, production of bile salts, heme catabolism
and metabolites generated via the gut microbiome. Asthmatics in our
cohort tended to have lower levels of endogenous cortisone, which
is likely an effect of inhaled corticosteroid use. Identifying a metabo-
lomic profile characteristic of children with asthma has the potential
to uncover novel candidate pathways in asthma pathophysiology. In
the long-term, asthma metabolomics research may identify biomark-
ers that improve the efficacy of therapeutic regimens for children
with asthma, in turn decreasing the severity of asthma suffering and
healthcare costs in the United States and globally.
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